{"title":"High Frequency of RhoGAP Fusion and Muscularis Mucosae Invasion in pT1a Gastric Adenocarcinoma Harboring Lymph Node Metastasis.","authors":"Chiina Hata, Hiroto Noda, Kaoru Nakano, Seiji Sakata, Kazuma Moriya, Satoko Baba, Toshiaki Hirasawa, Manabu Takamatsu, Emiko Sugawara, Noriko Yamamoto, Souya Nunobe, Takuji Gotoda, Kenichi Ohashi, Kengo Takeuchi, Hiroshi Kawachi","doi":"10.1111/pin.70032","DOIUrl":null,"url":null,"abstract":"<p><p>Gastric cancer (GC) confined to the mucosa (pT1a-GC) has a low incidence (approximately 3%) of lymph node metastasis (LNM), making it a suitable candidate for endoscopic resection. However, the current risk stratification system inadequately identifies high-risk patients. Although RhoGAP fusion has been identified as a risk factor for LNM in pT1b-GC, its role in pT1a-GC remains unclear. In the present study, medical records of 1099 surgically resected pT1a-GC cases over 12 years were reviewed, identifying 33 cases (3.0%) with LNM. A case-control study compared these cases to 99 LNM-negative cases based on clinicopathological data. Histological reviews and fluorescence In Situ hybridization assays to evaluate RhoGAP fusions, represented by CLDN18::ARHGAP26, were conducted. Univariate analysis revealed significant associations between LNM and larger tumor size (> 30 mm), mixed histological type, muscularis mucosae invasion (MMI), microtubular-mucocellular histology, and RhoGAP fusion. Multivariate analysis identified RhoGAP fusion and MMI as independent LNM predictors. Among LNM-positive cases, RhoGAP fusion was observed in 51.5% (17/33) and was associated with younger age and less frequent MMI. In conclusion, RhoGAP fusion and MMI may be significant biomarkers for LNM in pT1a-GC. Incorporating these factors could enhance risk stratification and inform clinical management strategies for pT1a-GC.</p>","PeriodicalId":19806,"journal":{"name":"Pathology International","volume":" ","pages":"414-424"},"PeriodicalIF":3.4000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pin.70032","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Gastric cancer (GC) confined to the mucosa (pT1a-GC) has a low incidence (approximately 3%) of lymph node metastasis (LNM), making it a suitable candidate for endoscopic resection. However, the current risk stratification system inadequately identifies high-risk patients. Although RhoGAP fusion has been identified as a risk factor for LNM in pT1b-GC, its role in pT1a-GC remains unclear. In the present study, medical records of 1099 surgically resected pT1a-GC cases over 12 years were reviewed, identifying 33 cases (3.0%) with LNM. A case-control study compared these cases to 99 LNM-negative cases based on clinicopathological data. Histological reviews and fluorescence In Situ hybridization assays to evaluate RhoGAP fusions, represented by CLDN18::ARHGAP26, were conducted. Univariate analysis revealed significant associations between LNM and larger tumor size (> 30 mm), mixed histological type, muscularis mucosae invasion (MMI), microtubular-mucocellular histology, and RhoGAP fusion. Multivariate analysis identified RhoGAP fusion and MMI as independent LNM predictors. Among LNM-positive cases, RhoGAP fusion was observed in 51.5% (17/33) and was associated with younger age and less frequent MMI. In conclusion, RhoGAP fusion and MMI may be significant biomarkers for LNM in pT1a-GC. Incorporating these factors could enhance risk stratification and inform clinical management strategies for pT1a-GC.
期刊介绍:
Pathology International is the official English journal of the Japanese Society of Pathology, publishing articles of excellence in human and experimental pathology. The Journal focuses on the morphological study of the disease process and/or mechanisms. For human pathology, morphological investigation receives priority but manuscripts describing the result of any ancillary methods (cellular, chemical, immunological and molecular biological) that complement the morphology are accepted. Manuscript on experimental pathology that approach pathologenesis or mechanisms of disease processes are expected to report on the data obtained from models using cellular, biochemical, molecular biological, animal, immunological or other methods in conjunction with morphology. Manuscripts that report data on laboratory medicine (clinical pathology) without significant morphological contribution are not accepted.